| 99.99 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 116.79 | 1-year : | 136.42 |
| Resists | First : | 100 | Second : | 116.79 |
| Pivot price | 99.98 | |||
| Supports | First : | 99.98 | Second : | 99.97 |
| MAs | MA(5) : | 99.98 | MA(20) : | 99.98 |
| MA(100) : | 99.98 | MA(250) : | 96.02  |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 66.6 | D(3) : | 66.6 |
| RSI | RSI(14): 78.9 | |||
| 52-week | High : | 100 | Low : | 48.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARNA ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 100.09 - 100.58 | 100.58 - 101 |
| Low: | 98.78 - 99.36 | 99.36 - 99.85 |
| Close: | 99.14 - 100.02 | 100.02 - 100.78 |
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Thu, 25 Apr 2024
If You Had Bought Arena Pharmaceuticals (NASDAQ:ARNA) Shares Three Years Ago You'd Have Made 283% - Yahoo Movies Canada
Tue, 18 Jan 2022
Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline - Nasdaq
Tue, 21 Dec 2021
Pfizer Acquires Arena At A 100% Premium (NASDAQ:ARNA) - Seeking Alpha
Mon, 13 Dec 2021
Pfizer to Buy Arena at 100% Premium in $6.7 Billion Deal - Bloomberg
Mon, 13 Dec 2021
Pfizer to Acquire Arena Pharmaceuticals - Business Wire
Tue, 27 Jul 2021
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -248 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 6.166e+007 (%) |
| Held by Institutions | 6.152e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.1945e+008 |
| EPS Est Next Qtrly | -0.67 |
| EPS Est This Year | -2.95 |
| EPS Est Next Year | -2.74 |
| Book Value (p.s.) | -10.15 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 10 % |
| Return on Equity (ttm) | 483.2 % |
| Qtrly Rev. Growth | -70.4 % |
| Gross Profit (p.s.) | -5.26 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.65 |
| Qtrly Earnings Growth | -5.4179e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -9.87 |
| Price to Sales | 166362 |
| Price to Cash Flow | 0 |
| Dividend | 6.02e+006 |
| Forward Dividend | 5.11e+006 |
| Dividend Yield | 6020600% |
| Dividend Pay Date | 2017-06-18 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|